Westaim Corporation (WEDXF)

[JustinFab]

I believe Westaim reports earnings 3/25/2021. Seems like good things are happening with Arena and Skyward Insurance. I am looking forward to seeing the numbers.

[Enterprising Investor]

The Westaim Corporation Reports 2019 Second Quarter Results (8/07/19)

https://westaim.com/wp-content/uploads/Westaim-Q2-2019-press-release-FINAL.pdf

[Enterprising Investor]

Investor Presentation (5/2019)

https://westaim.com/wp-content/uploads/Westaim-Corporate-Update-Website-Post-30-May-1.pdf

[Enterprising Investor]

2019 Top Pick (12/31/18)

https://seekingalpha.com/article/4229626-2019-top-pick

[barnovage]

Anyone still lurking. Anyone long?

[Renee]

WEDXF one for 50 reverse split:

http://www.otcbb.com/asp/dailylist_detail.asp?d=09/30/2013&mkt_ctg=NON-OTCBB

[originunknown]

HUGE volume today -- buyback in progress???

[StormyMonday]

Frogfan thanks for that info.....wish I was in it...

[frogfan]

up because NCST, of which WEDX owns 74%, was up 161% today...people found this out and started buying WEDX...NCST was up huge on news of FDA approval, and WEDX was up because it owned most of NCST...

BANGALORE, July 20 (Reuters) - Shares of Nucryst Pharmaceuticals Corp. (NCST.O: Quote, Profile, Research) doubled their value on Friday, a day after its antimicrobial cream received approval from U.S. health regulators.

The cream, a formulation of nanocrystalline silver NPI 32101, was previously being studied as a treatment for dermatitis but failed in a mid-stage trial in September 2006, prompting the company to discontinue further studies.

" ...it failed to show statistical significance as an anti-inflammatory (treatment), but we did know its antimicrobial properties prior to that," company spokesman David Wills said by phone.

After the failure of the trial, Nucryst focused on seeking approval for the product as a medical device that acts as a barrier to infection from a broad spectrum of microbes, Willis added.

Before today's gains, Nucryst shares had lost about 80 percent of their value since the failure of the trial.

The company has not determined the timing of the product's launch, Nucryst said in a statement.

Shares of the company were up $2.28 at $4.54 in midday trade, making it the highest percentage gainer on the Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore)

[StormyMonday]

up 62% on 5.3 mil shares with NO NEWS!!! Somebody knows something

[Hoop]

I have no idea. I wish I was back in it though.

[StormyMonday]

Hoop, .80 pre market..Whats da buzz on this?

[Hoop]

Hopefully this will free up some cash until next year without management needing to delute...

The Westaim Corporation sells Fort Saskatchewan real estate holdings for $13.5M 5/8/2007
Download this Press Release


CALGARY, May 8 /PRNewswire-FirstCall/ - The Westaim Corporation announced today it has sold its real estate holdings in Fort Saskatchewan, Alberta, for net proceeds of $13.5 million. The company will record a book gain of approximately $7.5 million on the transaction.

"As part of our review of the company's business strategy, we determined that our Fort Saskatchewan real estate assets are no longer key to our future plans," said Barry M. Heck, President & CEO, The Westaim Corporation. "We believe it is in the best interest of Westaim's shareholders to realize the value of this non-core asset to strengthen our balance sheet. The facility is partially occupied by NUCRYST Pharmaceuticals which will continue as a tenant under existing long-term leases."

On April 23, 2007, Westaim announced it was conducting a strategic review of its business strategy to determine the optimal use of existing resources and assets to maximize value for shareholders. At March 31, 2007, Westaim had $51.7 million in consolidated cash and short-term investments, which includes $21.2 million of NUCRYST Pharmaceuticals Corp. cash and short-term investments. The gain on the sale will be recorded in the second quarter of 2007.

Hoop

[originunknown]

Westaim will need good news to prop NASDAQ listing. I bought today on Canadian side for the bounce.

100M is the o/s and the bottom is here.

If anybody still reads this board, I am mystified by the variety of holdings by this company. Biomedical (wound care) and electronic (iFire panels)?

[Bridgejumper]

Just testing ...



Cheers

The Bridgejumper

[Hoop]

THE HOTSHEET from Getatip.net
For Thursday December 28, 2006

Bringing you 16 years of investment experience and hours of after the close research in one HOTSHEET

NOTES:

• Check in periodically on the Getatip Blog throughout the day, if come across anything interesting I’ll Blog it.

BREAKOUTS

BLUD (Immucor Inc.) Broke out at 30


BOUNCE OFF BOTTOM OR SUPPORT

WEDX (Westaim Corp) Exploded off a double bottom on over 7X normal volume. Minor resistance is 1.88 then 2.25 after that it’s 3.5 – If it trades over average volume (74,000) by noon or before and pushes the resistance levels we could have a blast off. I know I sound like a broken record, but as tax loss selling eases so does the overhead resistance, that is why we are seeing these big pops over the last few days.

TBV (Tiens Biotech) Over 3.60 could send this Chinese nutritional supplement company into orbit. The volume was about 3X normal yesterday. Volume often precedes and gives a heads up on pending breakouts.

RADN (Radyne Corp) Over 10.45

QTWW (Quantum Fuel System Tech) Over 1.80


SPECIAL SITUATION

Visit the past SPECIAL SITUATION BLOG


MDWV (Medwave Inc.) Was mentioned on the “Friday Movers Blog” at 10.55 am at .54 and ran to a high of .80 on the day before settling down and closing at .57 Volume was over 14X normal. I’m not sure what the market for their non invasive vital sign monitor is but its most likely over their market cap which is 7.6 million and as the stock is down from a high of over 10 in April of 2004 I’d say it’s a pretty good candidate for one hell of a bounce as tax loss selling eases.


INSIDER BUYING

I went through the 52 companies that fit the Reuters Insider buying screen and looked at the insider activity, chart pattern and volume over the last few days and these stood out. If anyone has a good search platform for scanning for insider buying please let me know.



GLGC (Gene Logic Inc.) A fair amount of insider buying over the last few months around 1.40

CHID (China Digital Communication Group) The President of the company has been buying shares since .95 back in May to his recent purchase at .22




For other, more complete lists of companies with insider buying see, Reuters complete list Or at SEC Form 4 which has a great layout that is updated daily.



These are not recommendations, rather the starting point for your research. The prices mentioned are simply trigger points that may have a technical significance. We may be buying or selling these positions at any time during the day including before or after the prices mentioned as a trigger point or a possible target. Extrapolations of earnings into price targets are very basic observations and not intended to be buy or sell recommendations. Our views change on a dime. This is intended to be the starting point for your research. We are not responsible for your investment decisions and are not acting in an advisory capacity. We are not giving investment advice rather ideas for you to follow up on with a professional or to research on your own. The information provided is believed to be reliable but we make no guarantee as to its accuracy. It is your responsibility to check all facts and figures for correctness and errors. This sheet is something I put together for my own use and decided to share

[Hoop]

Good post from another board:

1. Yes, Westaim's investment in NCST is only worth $56MM at the current market price. The remainder is $100MM. However, since Westaim has $50MM cash (in addition to $20MM cash held by its subsidiary NCST), the market thinks that IFire is only worth $50MM. However, analysts think that Westaim's stake in NCST is worth $170MM and IFire is worth $720MM.

2. The SEC filings tell the story:

< In February 2005, a wholly owned subsidiary of the Company issued $6,000 of convertible debentures to private investors. These debentures mature in February 2007, bear interest at 5% per annum, have no recourse to the Company and are convertible into a maximum of 12,000,000 non-voting common shares of the inactive subsidiary. If converted, the Company’s economic interest in the inactive subsidiary would be reduced to approximately 22% and the Company’s consolidated non-capital losses and research and development tax credits would be reduced by approximately $91,000 and $18,000, respectively. These convertible debentures are financial instruments which have both debt and equity components. The value assignable to the conversion option at the date of issue was determined to be immaterial. Interest expense on these debentures during 2005 amounted to $206 and was accrued in accounts payable and accrued liabilities at December 31, 2005. >


< In February 2005, a wholly owned subsidiary of the Company issued $6,000 of convertible debentures to private investors and in the second quarter of 2006 issued an additional $2,000 of convertible debentures. Of the $8,000 of convertible debentures outstanding on September 30, 2006, $251 is owned directly or indirectly by Officers of the Company. These debentures mature in July 2007, bear interest at 5% per annum, have no recourse to the Company and are convertible into a maximum of 16,000,000 non-voting common shares of the subsidiary. If converted, the Company’s economic interest in the subsidiary would be reduced to approximately 17.5% and the Company’s consolidated non-capital losses and research and development tax credits would be reduced by approximately $92,000 and $18,000 respectively. These convertible debentures are financial instruments which have both debt and equity components. The value assignable to the conversion option at the date of issue was determined to be immaterial. Interest expense on these debentures for the three months ended September 30, 2006 amounted to $101 (2005 — $76). Interest expense for the nine months ended September 30, 2006 amounted to $260 (2005 — $130). Interest paid in the third quarter of 2006 amounted to $148 and no interest was payable as at September 30, 2006. Subsequent to September 30, 2006, this subsidiary agreed to participate in a Plan of Arrangement with two unrelated parties. The proposed Plan of Arrangement will result in the reorganization of the participating companies into a proposed single new public company and the dilution of the Company’s investment in the new company to approximately 1.4%. Upon completion of the transaction, the investment will be carried at approximately $1,300, the Company’s pro rata interest in the book value of the new public company. The Company will also record a dilution gain of approximately $6,900, and $8,000 of convertible debentures and approximately $2,400 of cash of the subsidiary will no longer be consolidated in the Company’s consolidated balance sheet. The Plan of Arrangement is subject to regulatory, judicial and other approvals in the fourth quarter. >

IMO, the company owns a stake in some technology that they want to keep secret, and there is no dilution forthcoming.

[mick]

o.k.,,,thank you for the update. innovations make the world go round.

[Hoop]

They are working on phosphor models, I do believe...

[mick]

this led stuff?

[Hoop]

No, I got back 6 months ago. I need to update that. As far as fundamentals, the big word on this particular stock is that they are waiting on a JV partner. It seems they are very quiet as of late. I am not even sure that I see them selling a cheaper LCD screen is a good deal right now, considering the big boys are dropping their price...

[mick]

i looked at your profile.

are you still in japan?

[mick]

i think all should do well from the reading. now for some good fundamentals.

[Hoop]

Yea, looks bottom out to me...

[mick]

the chart needs to get the 50ema and 200ema closer together.

[mick]

hi hoop, looks like a btm call here. nice stuff.

[Hoop]

Just wanted to post the first message. I have been buying the last couple of weeks based on potential and a seemingly bottom line price.